Autopsy report · NCT04184518

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

“The Cediranib producer laboratory decided to stop the development of this product.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Grupo Español Multidisciplinar de Melanoma

Sponsor type

University, hospital or other

Conditions

Uveal Melanoma; Metastatic Cancer

Interventions

Cediranib Maleate; Durvalumab

Participants

0

Sites

5

Countries

Spain

Trials that died the same way

• The Study for Evaluate of Satety and Dfficacy of Hemostatic Device
  “The company stopped manufacturing the product” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.